Skip to Content
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 02/09/18
Quantitative Imaging Network (QIN)

QIN Cooperative Agreement

QIN Cooperative Agreement Terms and Conditions

The terms and conditions for the two program announcements for the QIN are found in each of the program announcements. For PAR-18-248:

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an “assistance” mechanism (rather than an “acquisition” mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients’ activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

  • Defining the overall research objectives and approaches;
  • Determining experimental approaches, setting milestones for tools/methods development, and overseeing the conduct of analyses of data and other steps related to tools/methods implementation;
  • Overseeing and coordinating the effort of the investigator's team and participating institutions to ensure optimal effort integration;
  • Overseeing the conduct of UG3/UH3 research projects and ensuring their scientific rigor;
  • Ensuring compliance with the applicable mandatory regulations (including protection of confidentiality of any clinical data);
  • Adhering to the NIH policies regarding intellectual property, data release, and other data/resource policies;
  • Submitting a comprehensive annual update report to the NCI Project Scientist (apart from the Non-Competing Progress Report RPPR and financial statements as required in the NIH Grants Policy Statement) for inclusion in the Annual QIN Overview Report.
  • Participate in webinars, annual meetings, and conference calls to share research findings with the research community
  • Notifying the NCI Project Staff Scientist approximately 60 days prior to the termination of the UG3 phase of the project that a review of milestones and progress must be scheduled.

Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

An NCI Project Scientist will be responsible for:

  • Providing advice to the awardees on specific scientific, analytical, and clinical issues, as appropriate;
  • Serving as a liaison between the UG3/UH3 awardees and the NCI;
  • Facilitating interactions, sharing of data, and other forms of scientific integration across the UG3/UH3 awardees;
  • Promoting collaborations/interactions with other NIH-supported initiatives or investigators and assisting with coordination of such efforts;
  • Advising awardees with regard to various regulatory and compliance issues;
  • Participating in teleconferences with PDs/PIs to monitor progress and facilitate cooperation; and
  • Monitoring progress of the projects towards meeting milestones and adherence to the strategic goals of the program.
  • Scheduling a committee to review the progress under the UG3 phase of the project. The review process is to be conducted and completed in accordance with Part 2 Section 1 of this FOA.

Additionally, an NCI Program Official will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. This NCI Program Official will be responsible for conducting a UG3 to UH3 transition review.

NCI reserves the right to phase out or curtail an individual award (including the UH3 phase) in the event of inability to meet milestones or insufficient progress towards meeting milestones.

Areas of Joint Responsibility include:

  • An Executive Committee (EC) will be the main governing board for the network. The EC will be jointly established by the lead PD/PIs of the awarded multi-disciplinary teams and selected NCI staff members.
  • The EC will consist of the following voting members:
  • Two representatives from each awarded team (e.g., one from the clinical center and the other from the basic science group), who will collectively have a single vote for each team; and
  • Two designated NCI Program staff members (Project Scientist[s] and Coordinator), who will collectively have one vote for the NIH.
  • The EC will elect one of the team investigators as its chair for a 1-year term annually during the period of the program.
  • Responsibilities of the EC will include:
  • Discuss progress of each team and make recommendations that encourage intra-team collaborations to enhance progress and consensus on validation methods;
  • Review and facilitate the efforts aimed at sharing of validation methods and related databases across the Network;
  • Review the efforts of the Research Resource teams during the course of their efforts;
  • Schedule and organize an annually meeting at which network members will present their scientific progress and future plans;
  • Schedule monthly telephone conference calls to coordinate the activities of the network.
  • All EC decisions and recommendations that require voting will be based on a majority vote.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Executive Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee’s right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR

For PAR-18-249:

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an “assistance” mechanism (rather than an “acquisition” mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients’ activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.

Primary Responsibilities of the PD(s)/PI(s)

Each of the PD(s)/PI(s) retains the primary responsibility, authority, and dominant role for planning, directing, and executing the activities of the award under this FOA. The PD(s)/PI(s) assume responsibility and accountability to the applicant organization officials and to the NCI for the performance and proper conduct of the research supported by the U01 award in accordance with these terms and conditions of the award.

Specific PD(s)/PI(s) responsibilities and rights will be to:

  • Define the overall research objectives and approaches;
  • Determine experimental approaches, setting milestones for tools/methods development, and overseeing the conduct of analyses of data and other steps related to tools/methods implementation;
  • Oversee and coordinate the effort of the investigator's team and participating institutions to ensure optimal effort integration;
  • Oversee the conduct of  research projects and ensuring their scientific rigor;
  • Ensure compliance with the applicable mandatory regulations (including protection of confidentiality of any clinical data);
  • Adhere to the NIH policies regarding intellectual property, data release, and other data/resource policies;
  • Submit a comprehensive annual update report to the NCI Project Scientist (apart from the Non-Competing Progress Report RPPR and financial statements as required in the NIH Grants Policy Statement) for inclusion in the Annual QIN Overview Report.
  • Participate in webinars, annual meetings, and conference calls to share research findings with the research community
  • Notify the NCI Project Staff Scientist approximately 60 days prior to the termination of the UG3 phase of the project that a review of milestones and progress must be scheduled. Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

Primary Responsibilities of the NCI Staff:

NCI staff, acting as Project Scientist will have scientific and programmatic involvement that is above and beyond the normal stewardship role in awards, as described below.

Specifically, the NCI Project Scientist will:

  • Provide advice to the awardees on specific scientific, analytical, and clinical issues, as appropriate;
  • Serve as a liaison between the U01 awardees and the NCI;
  • Facilitate interactions, sharing of data, and other forms of scientific integration across the U01 awardees;
  • Promote collaborations/interactions with other NIH-supported initiatives or investigators and assisting with coordination of such efforts;
  • Advise awardees with regard to various regulatory and compliance issues;
  • Participate in teleconferences with PDs/PIs to monitor progress and facilitate cooperation; and
  • Monitor progress of the projects towards meeting milestones and adherence to the strategic goals of the program.

Additionally, an NCI Program Director acting as the NIH Program Official will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. A Program Official may also have substantial programmatic involvement (as a Project Scientist) and may be the same person as Project Scientist.

NCI reserves the right to phase out or curtail an individual award in the event of inability to meet milestones or insufficient progress towards meeting milestones.

Areas of Joint Responsibility

The NCI Project Scientist and the PDs/PIs of the Cooperative Agreement awards funded under this FOA will be jointly responsible for the formation of an Executive Committee (EC) that will be the main governing board for the network.

The EC will be jointly established by the lead PD/PIs of the awarded multi-disciplinary teams and selected NCI staff members. The EC will consist of the following voting members:

  • Two representatives from each awarded team (e.g., one from the clinical center and the other from the basic science group), who will collectively have a single vote for each team; and
  • Two designated NCI Program staff members (Project Scientist[s] and Coordinator), who will collectively have one vote for the NIH.

The EC will elect one of the team investigators as its chair for a 1-year term annually during the period of the program.

Responsibilities of the EC will include the following:

  • Discuss progress of each team and make recommendations that encourage intra-team collaborations to enhance progress and consensus on validation methods;
  • Review and facilitate the efforts aimed at sharing of validation methods and related databases across the Network;
  • Review the efforts of the Research Resource teams during the course of their efforts;
  • Schedule and organize an annually meeting at which network members will present their scientific progress and future plans;
  • Schedule monthly telephone conference calls to coordinate the activities of the network; and
  • All EC decisions and recommendations that require voting will be based on a majority vote.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Executive Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee’s right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR.